Congressman Kean Jr. Reveals Depression Diagnosis After Absence

Major depressive disorder (MDD) is a complex psychiatric illness characterized by persistent low mood, anhedonia, changes in sleep and appetite, fatigue, and impaired concentration. These symptoms must be present for at least two weeks and represent a change from previous functioning, causing clinically significant distress or impairment in social, occupational, or other important areas of functioning. The World Health Organization estimates that over 280 million people worldwide experience depression, making it a significant public health burden.¹

The etiology of MDD is multifactorial, involving a combination of genetic predisposition, neurobiological factors, environmental stressors, and psychological vulnerabilities. Neurotransmitter imbalances, particularly involving serotonin, norepinephrine, and dopamine, have long been implicated, though current understanding extends to neural circuit dysfunction and inflammatory pathways. Diagnosis relies on clinical assessment against criteria outlined in diagnostic manuals such as the DSM-5 or ICD-11, typically involving a detailed patient history and mental status examination.²

The Clinical Reality of Depression

Treatment for MDD typically involves a combination of psychotherapy, pharmacotherapy, or both. Selective serotonin reuptake inhibitors (SSRIs) are often first-line pharmacologic agents, working by increasing serotonin levels in the synaptic cleft. Other antidepressant classes include serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs), each with distinct mechanisms of action and side effect profiles. The choice of treatment depends on symptom presentation, patient comorbidities, previous treatment response, and potential drug interactions.³

Psychotherapeutic approaches, such as cognitive behavioral therapy (CBT) and interpersonal therapy (IPT), teach patients coping strategies, help identify maladaptive thought patterns, and improve interpersonal relationships. These therapies can be highly effective, either alone or in conjunction with medication, particularly for mild to moderate depression. For severe or treatment-resistant depression, options expand to include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and ketamine or esketamine treatments, which have shown efficacy in specific patient populations.⁴

The public disclosure by Representative Tom Kean Jr. of his depression diagnosis, following a four-month absence from his congressional duties, underscores the pervasive nature of this illness, even among high-functioning individuals. His statement, released through his office, cited a need for personal time to address his mental health. This transparency from a public figure can significantly contribute to reducing the stigma often associated with mental health conditions, encouraging others to seek help without fear of professional or social repercussions.⁵

Kean Jr.'s experience reflects a common challenge: the difficulty of maintaining demanding professional responsibilities while managing a significant mental health condition. The decision to step away from public life, even temporarily, for treatment highlights the severity of symptoms that can necessitate such a break. This is not an isolated incident; numerous public figures and professionals have shared similar struggles, slowly chipping away at the societal taboo.⁶

But the impact of such disclosures extends beyond individual cases. It can influence public policy, potentially leading to increased funding for mental health services, improved access to care, and greater integration of mental health into primary care settings. The conversation shifts from one of personal failing to one of medical necessity, aligning mental health with other chronic medical conditions that require ongoing management and support.⁷

Still, challenges persist. Despite growing awareness, many individuals with depression do not receive adequate treatment due to barriers such as cost, lack of access to specialists, and persistent societal stigma. The average delay between symptom onset and treatment initiation can be years, during which time the illness can become more entrenched and difficult to treat. This delay often leads to greater functional impairment and a higher risk of comorbidity with other physical and mental health conditions.⁸

The open discussion of depression by figures like Kean Jr. helps to normalize the experience, making it easier for patients to discuss their symptoms with their general practitioners. GPs are often the first point of contact for individuals experiencing mental health issues, and their role in early detection, initial management, and referral to specialist care is critical. Training for GPs in mental health first aid and evidence-based screening tools remains a priority.⁹

The long-term prognosis for MDD varies. With appropriate treatment, many individuals achieve remission and maintain good quality of life. But recurrence rates are high, particularly for those with a history of multiple episodes or chronic symptoms. Ongoing management, including adherence to medication, regular therapy, and lifestyle adjustments, is often necessary to prevent relapse. The public conversation initiated by Kean Jr. must translate into sustained efforts to improve mental health literacy and access to care across all demographics.¹⁰